AI-generated summary
This critical narrative review examines whether the oral microbiome plays a role in how photobiomodulation responds during cancer supportive care, focusing on oral mucositis. The authors report that direct clinical evidence is sparse and mixed, with one small uncontrolled pilot showing concurrent cytokine and microbiome shifts and a case series showing clinical improvement without significant changes in salivary bacterial community structure. They conclude that microbiome change should be treated as an emerging hypothesis and research endpoint rather than an established mechanism.
- Who or what was studied
- Patients receiving cancer therapy, including those with oral mucositis and head-and-neck cancer
- Limits stated in the abstract
- The abstract describes sparse, internally mixed direct evidence, including a four-patient uncontrolled pilot, and states that causal interpretation requires longitudinal sampling, functional assays and complete dosimetry.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Oral mucositis, Photodynamic therapy, Irradiance, Wavelength, Biomarker, Dosimetry. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.